Search research articles
Contact Us
Filters
Showing results (31-40 of 41) with videos related to
Page
of 5
Sort By:
JAMA Oncology
|
October 14, 2016
Association of Proton Pump Inhibitors and Capecitabine Efficacy in Advanced Gastroesophageal Cancer: Secondary Analysis of the TRIO-013/LOGiC Randomized Clinical Trial
Michael P Chu, J Randolph Hecht, Dennis Slamon, et al.
The Lancet. Oncology
|
June 21, 2015
Combination of everolimus with trastuzumab plus paclitaxel as first-line treatment for patients with HER2-positive advanced breast cancer (BOLERO-1): a phase 3, randomised, double-blind, multicentre trial
Sara A Hurvitz, Fabrice Andre, Zefei Jiang, et al.
The New England Journal of Medicine
|
October 14, 2011
Adjuvant trastuzumab in HER2-positive breast cancer
Dennis Slamon, Wolfgang Eiermann, Nicholas Robert, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
June 4, 2019
Neoadjuvant Trastuzumab Emtansine and Pertuzumab in Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer: Three-Year Outcomes From the Phase III KRISTINE Study
Sara A Hurvitz, Miguel Martin, Kyung Hae Jung, et al.
BMC Cancer
|
October 12, 2018
Development of acquired resistance to lapatinib may sensitise HER2-positive breast cancer cells to apoptosis induction by obatoclax and TRAIL
Alex J Eustace, Neil T Conlon, Martina S J McDermott, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
December 3, 2015
Lapatinib in Combination With Capecitabine Plus Oxaliplatin in Human Epidermal Growth Factor Receptor 2-Positive Advanced or Metastatic Gastric, Esophageal, or Gastroesophageal Adenocarcinoma: TRIO-013/LOGiC--A Randomized Phase III Trial
J Randolph Hecht, Yung-Jue Bang, Shukui K Qin, et al.
JAMA Oncology
|
December 1, 2022
Tucatinib vs Placebo, Both in Combination With Trastuzumab and Capecitabine, for Previously Treated ERBB2 (HER2)-Positive Metastatic Breast Cancer in Patients With Brain Metastases: Updated Exploratory Analysis of the HER2CLIMB Randomized Clinical Trial
Nancy U Lin, Rashmi K Murthy, Vandana Abramson, et al.
Cancer Cell
|
February 16, 2017
Characterization of Human Cancer Cell Lines by Reverse-phase Protein Arrays
Jun Li, Wei Zhao, Rehan Akbani, et al.
The New England Journal of Medicine
|
March 20, 2024
Ribociclib plus Endocrine Therapy in Early Breast Cancer
Dennis Slamon, Oleg Lipatov, Zbigniew Nowecki, et al.
The New England Journal of Medicine
|
December 12, 2019
Tucatinib, Trastuzumab, and Capecitabine for HER2-Positive Metastatic Breast Cancer
Rashmi K Murthy, Sherene Loi, Alicia Okines, et al.
Page
of 5
Search research articles
Search
Showing results (31-40 of 41) with videos related to
Sort By:
Page
of 5
JAMA Oncology
|
October 14, 2016
Association of Proton Pump Inhibitors and Capecitabine Efficacy in Advanced Gastroesophageal Cancer: Secondary Analysis of the TRIO-013/LOGiC Randomized Clinical Trial
Michael P Chu, J Randolph Hecht, Dennis Slamon, et al.
The Lancet. Oncology
|
June 21, 2015
Combination of everolimus with trastuzumab plus paclitaxel as first-line treatment for patients with HER2-positive advanced breast cancer (BOLERO-1): a phase 3, randomised, double-blind, multicentre trial
Sara A Hurvitz, Fabrice Andre, Zefei Jiang, et al.
The New England Journal of Medicine
|
October 14, 2011
Adjuvant trastuzumab in HER2-positive breast cancer
Dennis Slamon, Wolfgang Eiermann, Nicholas Robert, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
June 4, 2019
Neoadjuvant Trastuzumab Emtansine and Pertuzumab in Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer: Three-Year Outcomes From the Phase III KRISTINE Study
Sara A Hurvitz, Miguel Martin, Kyung Hae Jung, et al.
BMC Cancer
|
October 12, 2018
Development of acquired resistance to lapatinib may sensitise HER2-positive breast cancer cells to apoptosis induction by obatoclax and TRAIL
Alex J Eustace, Neil T Conlon, Martina S J McDermott, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
December 3, 2015
Lapatinib in Combination With Capecitabine Plus Oxaliplatin in Human Epidermal Growth Factor Receptor 2-Positive Advanced or Metastatic Gastric, Esophageal, or Gastroesophageal Adenocarcinoma: TRIO-013/LOGiC--A Randomized Phase III Trial
J Randolph Hecht, Yung-Jue Bang, Shukui K Qin, et al.
JAMA Oncology
|
December 1, 2022
Tucatinib vs Placebo, Both in Combination With Trastuzumab and Capecitabine, for Previously Treated ERBB2 (HER2)-Positive Metastatic Breast Cancer in Patients With Brain Metastases: Updated Exploratory Analysis of the HER2CLIMB Randomized Clinical Trial
Nancy U Lin, Rashmi K Murthy, Vandana Abramson, et al.
Cancer Cell
|
February 16, 2017
Characterization of Human Cancer Cell Lines by Reverse-phase Protein Arrays
Jun Li, Wei Zhao, Rehan Akbani, et al.
The New England Journal of Medicine
|
March 20, 2024
Ribociclib plus Endocrine Therapy in Early Breast Cancer
Dennis Slamon, Oleg Lipatov, Zbigniew Nowecki, et al.
The New England Journal of Medicine
|
December 12, 2019
Tucatinib, Trastuzumab, and Capecitabine for HER2-Positive Metastatic Breast Cancer
Rashmi K Murthy, Sherene Loi, Alicia Okines, et al.
Page
of 5